Cited by 495Ovarian function and disordersEndometriosis Research and TreatmentGenetic and Kidney Cyst Diseases

Polycystic ovary syndrome

Open access
Stener-Victorin, Elisabet, Teede, Helena, Norman, Robert J., Legro, Richard, Goodarzi, Mark O., Dokras, Anuja, Laven, Joop, Hoeger, Kathleen +1 more·2024·Nature Reviews Disease Primers

Abstract

Despite affecting ~11-13% of women globally, polycystic ovary syndrome (PCOS) is a substantially understudied condition. PCOS, possibly extending to men's health, imposes a considerable health and economic burden worldwide. Diagnosis in adults follows the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, requiring two out of three criteria - clinical or biochemical hyperandrogenism, ovulatory dysfunction, and/or specific ovarian morphological characteristics or elevated anti-Müllerian hormone. However, diagnosing adolescents omits ovarian morphology and anti-Müllerian hormone considerations. PCOS, marked by insulin resistance and hyperandrogenism, strongly contributes to early-onset type 2 diabetes, with increased odds for cardiovascular diseases. Reproduction-related implications include irregular menstrual cycles, anovulatory infertility, heightened risks of pregnancy complications and endometrial cancer. Beyond physiological manifestations, PCOS is associated with anxiety, depression, eating disorders, psychosexual dysfunction and negative body image, collectively contributing to diminished health-related quality of life in patients. Despite its high prevalence persisting into menopause, diagnosing PCOS often involves extended timelines and multiple health-care visits. Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome. Identifying factors contributing to PCOS will pave the way for personalized medicine approaches. Additionally, exploring novel biomarkers, refining diagnostic criteria and advancing treatment modalities will be crucial in enhancing the precision and efficacy of interventions that will positively impact the lives of patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41572-024-00511-3

Cites

308 of 308 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T.
Affiliations
  • Monash Health (AU)
  • Pennsylvania State University (US)
  • Cedars-Sinai Medical Center (US)
  • University of Pennsylvania (US)
  • Erasmus MC (NL)
  • University of Rochester Medicine (US)
  • Oulu University Hospital (FI)
Venue
Nature Reviews Disease Primers
Published
2024-04-18
Volume
10
Issue
1
Pages
27-27
ISSN
2056-676X (ISSN-L)
OpenAlex
W4394931560
Cited by
495
References
308
Citations by year
2026: 234 · 2025: 212 · 2024: 42 · 2019: 3 · 2013: 1 · 2012: 1
FWCI
34.33
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
Funders
  • Karolinska Institutet (2020-00990)
  • Novo Nordisk
  • Stockholms Läns Landsting
  • Novo Nordisk Fonden (NNF21OC0070372, NNF22OC0072904, NNF18OC0033992, NNF19OC0056647)
  • Medical Research Council
  • National Health and Medical Research Council (2009326)
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords
polycystic ovary syndrome, hyperandrogenism, insulin resistance, type 2 diabetes, cardiovascular disease, anovulatory infertility, pregnancy complications, endometrial cancer, mental health, quality of life, anti-Müllerian hormone, diagnostic criteria, pathophysiology, biomarkers, personalized medicine, menopause
MeSH terms
Adolescent, Adult, Diabetes Mellitus, Type 2, Female, Humans, Polycystic Ovary Syndrome, Pregnancy, Quality of Life, Hyperandrogenism, Anti-Mullerian Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review